Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

907 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Leeksma AC, et al. Among authors: gonen m. Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23. Leukemia. 2019. PMID: 30038380 Free PMC article.
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O'Connor OA. Paoluzzi L, et al. Among authors: gonen m. Blood. 2008 Jun 1;111(11):5350-8. doi: 10.1182/blood-2007-12-129833. Epub 2008 Feb 21. Blood. 2008. PMID: 18292288 Free article.
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL. Marubayashi S, et al. Among authors: gonen m. J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13. J Clin Invest. 2010. PMID: 20852385 Free PMC article.
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Patel JP, et al. Among authors: gonen m. N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14. N Engl J Med. 2012. PMID: 22417203 Free PMC article.
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Zhang SJ, et al. Among authors: gonen m. Blood. 2012 May 10;119(19):4480-5. doi: 10.1182/blood-2011-11-390252. Epub 2012 Mar 19. Blood. 2012. PMID: 22431577 Free PMC article.
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Koppikar P, et al. Among authors: gonen m. Nature. 2012 Sep 6;489(7414):155-9. doi: 10.1038/nature11303. Nature. 2012. PMID: 22820254 Free PMC article.
907 results